Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of Toothpaste Effect in Volunteers With Dental Sensitivity

18 maj 2026 uppdaterad av: Lacer S.A.

Comparative Clinical Trial to Evaluate the Efficacy of a Toothpaste in Subjects With Dental Hipersensitivity

The goal of this study is to learn if a toothpaste alone and together with mouthwash works to alleviate teeth hypersensitivity in adults. It will also learn about the safety of the product.

The main question it aims to answer is:

• Does the toothpaste help to improve signs of teeth hypersensitivity? Researchers will compare sensitive teeth toothpaste and use of sensitive teeth and mouthwash to a regular toothpaste to see if it works to improve teeth sensitivity.

Participants will:

  • Use assigned products daily for 14 days
  • Visit the clinic on the established days during 14 days for check-ups and evaluation

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

71

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Barcelona, Spanien
        • Hospital Odontológico Universidad de Barcelona - Bellvitge

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Healthy female and male participants (no specific gender distributions required)
  • Aged 18 years or older
  • Participants presenting dental hyperesthesia with at least two hypersensitive teeth with a verbal rating scale (VRS) score greater than or equal to 1 after tactile stimulation, and a Schiff Cold Air Sensitivity Scale score greater than or equal to 1 at the initial visit (T0).
  • Participants certifying the truthfulness of the personal data disclosed to the investigator.
  • Participants able to understand the language used at the investigation centre and comprehend the information provided by the investigator.
  • Participants able to follow the instructions provided by the investigator and comply with the study requirements and restrictions.
  • Pharmacological therapy (except for therapies listed under non-inclusion criteria) must have been stable for at least one month, with no changes expected or planned during the study
  • Commitment by the participants not to change the daily routine or lifestyle during the study.
  • Participants who have not taken part in any other similar clinical study in the previous six months.
  • Commitment by the participant not to use other oral hygiene products containing fluoride or ingredients such as hydroxyapatite during the study period.

Exclusion Criteria:

  • Participants currently participating or planning to participate in other clinical trials.
  • Participants deprived of liberty by administrative or judicial decision or under guardianship.
  • Participants who cannot be contacted in the event of an emergency.
  • Participants admitted to a healthcare or social institution.
  • Participants planning hospitalization during the study period.
  • Participants who have taken part in a similar study without respecting an adequate washout period (defined as the use of desensitizing agents within the last six months).
  • Participants under pharmacological treatments that modify the evaluation of dental sensitivity or are incompatible with the requirements of the study.
  • Participants with a history of active caries within the past 12 months or at risk for developing caries (e.g., multiple dental restorations, crowns with compromised margins) per examiners discretion.
  • Participants with known allergies or sensitivities to any components of the investigational product.
  • Women who are breastfeeding, pregnant, or unwilling to take the adequate contraceptive measures to avoid pregnancy during the study (for women of childbearing potential).
  • Participants with acute, chronic, or progressive pathologies (including diabetes, cardiovascular and metabolic conditions) incompatible with the study requirements.
  • Any tooth surface adjacent to those surfaces under investigation that in the opinion of the investigator have any other condition that produce symptoms confounding the evaluation of cervical dentin hypersensitivity.
  • Participants with a medical history or taking medication, or wearing physical items (e.g., orthodontic braces) that could interfere with the study.
  • Participants with a history of illegal drug use.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Vanlig tandkräm
Toothpaste was used two times a day (after meals) during 14 days
Experimentell: Desensitizing toothpaste
Toothpaste was used two times a day (after meals) during 14 days
Experimentell: Desensitizing toothpaste with mouthwash
Toothpaste and mouthwash were used two times a day (after meals) during 14 days

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Change from Baseline in dentine sensitivity comparing desensitizing toothpaste versus active comparator at 14 days
Tidsram: From enrollment to the end of use at 14 days
From enrollment to the end of use at 14 days

Sekundära resultatmått

Resultatmått
Tidsram
Change in dentine sensitivity from baseline in dentine sensitivity comparing desensitizing toothpaste group versus desensitizing toothpaste and mouthwash group at day 14.
Tidsram: From baseline to day 14
From baseline to day 14
Change from baseline in pH at 14 days
Tidsram: From baseline to day 14
From baseline to day 14

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 februari 2025

Primärt slutförande (Faktisk)

30 april 2025

Avslutad studie (Faktisk)

30 april 2025

Studieregistreringsdatum

Först inskickad

11 maj 2026

Först inskickad som uppfyllde QC-kriterierna

11 maj 2026

Första postat (Faktisk)

18 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Only summary of the results to support the publication will be shared. No complete study documents will be shared.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera